Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181226 | 0.82 | AAK1 (0.55) | HDAC1HDAC3HDAC2HDAC4HDAC6 | |
| SCHEMBL28619986 | 0.81 | NPC1 (0.40) | HDAC1HDAC3HDAC2HDAC4HDAC6 | |
| SCHEMBL20164158 | 0.81 | NPC1 (0.40) | HDAC1HDAC3HDAC2HDAC4HDAC6 | |
| SCHEMBL20164194 | 0.79 | ALDH1A1 (0.42) | HDAC1HDAC3 | |
| SCHEMBL20164187 | 0.78 | KDM4E (0.37) | — | |
| SCHEMBL20164184 | 0.78 | KDM4E (0.37) | — | |
| SCHEMBL28615071 | 0.75 | HDAC1 (0.44) | HDAC1HDAC3HDAC2HDAC4HDAC6 | |
| SCHEMBL28615072 | 0.75 | HDAC1 (0.44) | HDAC1HDAC3HDAC2HDAC4HDAC6 | |
| SCHEMBL20164144 | 0.73 | NPSR1 (0.34) | — | |
| SCHEMBL20164151 | 0.73 | NPSR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | HDAC1 1157/4885HDAC3 1419/4885HDAC2 696/4885 |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | TFPI, TFPI2, F11 | HDAC1 1157/4885HDAC3 1419/4885HDAC2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.